Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.46 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474126 | 0.87 | MAPT (0.48) | LRRK2PLAURMEN1MAPTKMT2A | |
| SCHEMBL16184421 | 0.86 | ABCB1 (0.44) | MAPTCYP11B1CYP11B2 | |
| SCHEMBL16186442 | 0.85 | ABCB1 (0.46) | MAPTCYP11B1CYP11B2 | |
| SCHEMBL16184827 | 0.85 | MKNK1 (0.52) | MAPTCYP11B1CYP11B2 | |
| SCHEMBL16184425 | 0.84 | ABCB1 (0.45) | LRRK2MAPTCYP11B1CYP11B2 | |
| SCHEMBL16184035 | 0.82 | CYP1A2 (0.48) | MEN1MAPTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL16183566 | 0.81 | CYP1A2 (0.47) | MEN1MAPTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL16184124 | 0.80 | CYP1A2 (0.46) | MEN1MAPTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL16184034 | 0.80 | CYP1A2 (0.47) | MEN1MAPTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL14474119 | 0.79 | CYP2C9 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | LRRK2 278/4885JAK2 1714/4885JAK1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.